Understanding Urothelial and Rare Genitourinary Cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to gather comprehensive data on the natural history of urothelial and rare genitourinary cancers, including various histological variants. Participants aged 18 and older with confirmed diagnoses of these cancers will undergo medical history screening, physical exams, and provide blood and urine samples. The study will also collect clinical photographs and family cancer history surveys to enhance understanding of these rare tumors and inform future treatment protocols.

Why it matters

Who can join: the full rules

* INCLUSION CRITERIA:
* Participants must have histologically or cytologically confirmed urothelial or rare genitourinary cancer including but not limited to the following: small cell carcinoma of the bladder; adenocarcinoma of the bladder; squamous cell carcinoma of the bladder; plasmacytoid urothelial carcinoma; any penile cancer; any testicular cancer, sarcomatoid renal cell carcinoma; sarcomatoid urothelial carcinoma; renal medullary carcinoma or other miscellaneous histologic variants of the urothelial carcinoma, such as, but not limited to micropapillary, giant cell, lipid-rich, clear cell and nested variants, large cell neuroendocrine carcinoma, lymphoepithelioma-like carcinoma and mixed patterns will be considered, as well as small cell neuroendocrine prostate cancer, testicular Sertoli or Leydig cell tumors. Any genitourinary cancer can be included at the principal investigator's discretion.
* Age \>=18 years.
* Ability of participant to understand and the willingness to sign a written informed consent document.

EXCLUSION CRITERIA:

-None

Where it's running

• National Institutes of Health Clinical Center
  Bethesda, Maryland, United States Recruiting

Study contacts

• Principal investigator: Andrea B Apolo, M.D. — National Cancer Institute (NCI)
• Study coordinator: Tzu-Fang Wang, R.N.
• Email: tzu-fang.wang@nih.gov
• Phone: (240) 858-3236

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• BL-M07D1: T-bren vs standard platinum chemo for HER2-expressing metastatic urothelial cancer after anti-PD-(L)1 therapy

  This trial tests whether T-bren can help people with HER2-expressing metastatic urothelial cancer who progressed after anti-PD-(L)1 therapy, compared with standard platinum-based chemotherapy.

  Recruiting at 2 sites Phase 3 SystImmune Inc. · Macon, Georgia and 1 other locations · NCT07869836

• Acupuncture and Exercise for EV-Pembro–Induced Peripheral Neuropathy

  This study tests whether adding acupuncture to a gentle virtual exercise program helps reduce chemotherapy-induced nerve problems in bladder cancer patients taking EV and pembrolizumab.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07548476

• Datopotamab deruxtecan plus carboplatin or cisplatin versus gemcitabine plus carboplatin or cisplatin for advanced or metastatic urothelial carcinoma

  This trial will test whether datopotamab deruxtecan with carboplatin or cisplatin works better than gemcitabine with carboplatin or cisplatin for people with advanced urothelial carcinoma who progressed during or after enfortumab vedotin plus pembrolizumab.

  Recruiting at 29 sites Phase 2/3 Daiichi Sankyo · Fullerton, California and 99 other locations · NCT07129993

• Sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial cancer

  This trial tests whether combining sacituzumab govitecan and enfortumab vedotin, with pembrolizumab in some patients, helps people with metastatic urothelial carcinoma who have progressed after platinum chemotherapy and PD‑1/PD‑L1 inhibitors.

  Recruiting Phase 1/2 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT04724018

• Understanding Urothelial Cancer through Tissue Collection

  This study is collecting tissue and other samples from people with urothelial cancer to see how the disease works and to help find better treatments.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT02379429

• Bladder cancer: test a biomarker-guided plan after neoadjuvant therapy

  This phase 2 study tests a biomarker- and response-guided plan to preserve the bladder in patients with muscle-invasive bladder cancer after neoadjuvant therapy.

  Recruiting Phase 2 Fox Chase Cancer Center · Philadelphia, Pennsylvania · NCT07908979

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.